Cargando…
Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
BACKGROUND: Schizophrenia patients are a population at particular risk of poor outcomes in COVID-19 infection. They have multiple comorbidities that have been identified as risk factors for severe COVID-19: diabetes, hypertension, chronic obstructive respiratory disease, and end-stage renal disease....
Autores principales: | Moga, Silvia, Teodorescu, Andreea, Ifteni, Petru, Gavris, Claudia, Petric, Paula-Simina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495225/ https://www.ncbi.nlm.nih.gov/pubmed/34629871 http://dx.doi.org/10.2147/NDT.S325062 |
Ejemplares similares
-
Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection
por: Moga, Silvia, et al.
Publicado: (2022) -
Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
por: Ifteni, Petru, et al.
Publicado: (2021) -
Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study
por: Miron, Ana Aliana, et al.
Publicado: (2023) -
Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania
por: Miron, Ana A., et al.
Publicado: (2022) -
Switch from Olanzapine Long-Acting Injectable to its Oral Equivalent during COVID-19 Pandemic: a Real World Observational Study
por: Miron, Ana-Aliana, et al.
Publicado: (2022)